Xiaoping Yi

Xiaoping Yi

Auto-generated profile, based on publicly available information

Xiaoping Yi

State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology (ECUST), Shanghai, People's Republic of China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Aquatic Toxicology
Verified
Journal Article
Closed access
KYKan Yu
Kan Yu
XLXiaoyong Li
Xiaoyong Li
YQYushu Qiu
Yushu Qiu
XZXinxin Zeng
Xinxin Zeng
XYXiaogang Yu
Xiaogang Yu
LHLisu Huang
Lisu Huang

13 August 2021 in Bioresources and Bioprocessing
Verified
Journal Article
Open access
PDF file
XTXiaonuo Teng
Xiaonuo Teng
CLChao Li
Chao Li
XYXiaoping Yi
Xiaoping Yi
YZYingping Zhuang
Yingping Zhuang
The scale-up of animal cell cultivation is important but remains complex and challenging. In the present study, we propose a novel scale-up strategy for baby hamster Syrian kidney-21 (BHK-21) cell cultivation based on similar hydrodynamic environments. The hydrodynamic characteristics of the different scale bioreactors were determined by computational fluid dynamics (CFD) and further correlated with the agitation speed. The optimal hydrodynamic environment for cell cultivation and vaccine production was determined from the cultivation experiments of BHK-21 cells in 5-L laboratory-scale bioreactors equipped with different impellers at various agitation speeds. BHK-21 cell cultivation was scaled up from 5-L to 42-, 350-, and 1000-L bioreactors by adjusting the agitation speed to make the hydrodynamic features similar to those in the 5-L bioreactor, especially for the shear rate in the impeller zone (γimp) and energy dissipation rate in the tank bulk zone (εtan). The maximum cell density and cell aggregation rate in these scaled-up bioreactors were in the range of 4.6 × 106 ~ 4.8 × 106 cells/mL and 16 ~ 20%, which are comparable to or even better than those observed in the 5-L bioreactor (maximum cell density 4.8 × 106 cells/mL, cell aggregation rate 21%). The maximum virus titer of 108.0 LD50/mL achieved in the 1000-L bioreactor was close to 108.3 LD50/mL that obtained in the 5-L bioreactor. Hence, the scale-up strategy proposed in this study is feasible and can efficiently facilitate the scale-up processes of animal cell cultivation.

8 October 2019 in Journal of Biotechnology
Verified
Journal Article
Closed access
ZDZhe Deng
Zhe Deng
XYXiaoping Yi
Xiaoping Yi
JCJu Chu
Ju Chu
YZYingping Zhuang
Yingping Zhuang


10 February 2025 in Human Gene Therapy
Verified
Journal Article
Closed access
ZDZhe Deng
Zhe Deng
YLYan-Ling Lv
Yan-Ling Lv
XWXin-Tao Wang
Xin-Tao Wang
LYLong-Hui Yuan
Long-Hui Yuan
KZKai Zhao
Kai Zhao
XXXiao Xiao
Xiao Xiao
Adeno-associated virus (AAV)–associated gene therapy has been increasingly promising, in light of the drugs progressed to clinical trials or approved for medications internationally. Therefore, scalable and efficient production of recombinant AAV is pivotal for advancing gene therapy. Traditional methods, such as the triple-plasmid transfection of human embryonic kidney 293 cells in suspension culture, have been widely employed but often hampered by low unit yield. In this study, we optimized the cell culture process with high cell density up to 2 × 10 7 cells/mL by employing a perfusion culture system with centrifugation and medium exchange in shake flasks and perfusion device in bioreactor. Furthermore, we utilized a design of experiments strategy to systematically modulate a series of transfection-related variables including the quantity of plasmid DNA, the DNA-to-polyethylenimine ratio, incubation duration, and the impact of post-transfection feeding strategies on the yield of recombinant AAV (rAAV). Our comprehensive analysis and subsequent optimizations actualized a remarkable unit yield reaching nearly 2 × 10 12 vector genomes (vg)/mL. Importantly, the resulting single-cell yield and biological activity were found to be comparable with those obtained from fed-batch cultures, underscoring the efficacy of our approach. Based on these findings, we investigated rAAV yield via high-density suspend culture in bioreactor, particularly focusing on cell aggregation and the use of perfusion technology. Intriguingly, we attempted to elevate the yield of an oversized recombinant coagulation factor VIII AAV843 vector by 3.5-fold, reaching a yield of 1 × 10 12 vg/mL. Concurrently, the medium usage rate was only double that of batch feeding, thereby significantly shrinking the upstream cost of rAAV manufacture. In summary, this strategy significantly benefits large-scale AAV production for both commercial and clinical applications.

1 June 2015 in Journal of Biotechnology
Verified
Journal Article
Closed access
YLYang Liu
Yang Liu
XYXiaoping Yi
Xiaoping Yi
YZYingping Zhuang
Yingping Zhuang
SZSiliang Zhang
Siliang Zhang